VaramirStart free · no cardSign in
TARS as of Nov 1 · 14:00 ET
TARSNasdaqBiological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc. · Brief

Next report

2 days

Nov 3 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
1 of 8≥ implied
avg implied
±13.4%
avg realized
±6.4%
Nov 13 '24±16.7%▲+0.31%×0.02
Feb 25 '25±15.8%▼−9.33%×0.59
May 1 '25±10.0%▼−5.84%×0.58
Aug 6 '25±12.6%▲+15.15%×1.20
Nov 4 '25±13.3%▼−4.62%×0.35
Feb 23 '26±14.8%▲+7.79%×0.53
Q1 FY26±13.4%▼−1.24%×0.09
Q2 FY26±10.5%▲+6.59%×0.63
quarterimplied−20%0+20%realized×
Q2 FY26±10.5%▲+6.59%×0.63
Q1 FY26±13.4%▼−1.24%×0.09
Feb '26±14.8%▲+7.79%×0.53
Nov '25±13.3%▼−4.62%×0.35
Aug '25±12.6%▲+15.15%×1.20
May '25±10.0%▼−5.84%×0.58
2 older reports
Feb '25±15.8%▼−9.33%×0.59
Nov '24±16.7%▲+0.31%×0.02
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 3

257managers reporting a position in the latest quarterly filings13F · Jun 30 '26
+7.94%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26

Bear2 of 3

31managers whose positions together make up four fifths of the reported value13F · Jun 30 '26
8 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

TARS report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 20impliedImplied move: ±16.2% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.